RT Book, Section A1 Minniti, Caterina P. A1 Hankins, Jane S. A2 Gladwin, Mark T. A2 Kato, Gregory J. A2 Novelli, Enrico M. SR Print(0) ID 1179345519 T1 Therapeutic Options and Combination Therapy T2 Sickle Cell Disease YR 2021 FD 2021 PB McGraw-Hill Education PP New York, NY SN 9781260458596 LK hemonc.mhmedical.com/content.aspx?aid=1179345519 RD 2024/10/06 AB The therapeutic landscape for patients with sickle cell disease (SCD) has recently expanded, and health care practitioners now have several options of disease-modifying drugs that are sickle cell specific. As of 2020, in the United States, there are 4 Food and Drug Administration (FDA)-approved drugs for patients living with SCD: hydroxyurea, L-glutamine,1 voxelotor,2 and crizanlizumab.3 Many more agents are currently being tested in phase II or III trials; therefore, we foresee that several new targeted therapies will be available by the end of the current decade. The treatment of individuals with SCD will become increasingly complex and, at the same time, mechanistically based, as a large number of these drugs are specifically being developed to affect and/or change the multifaceted pathophysiology of SCD.